Review maps epilepsy treatments, including cannabidiol, and genetics
Epilepsy with myoclonic-atonic seizures: a comprehensive review with emphasis on current and emerging pharmacotherapies.
AI Summary
This literature review examines epilepsy with myoclonic-atonic seizures (EMAtS), a childhood developmental and epileptic encephalopathy involving several generalized seizure types. Drawing on searches of PubMed, Embase, and OVID/MEDLINE, it summarizes the syndrome’s clinical features, diagnostic approach, genetic causes, and treatment options. The review covers commonly used antiseizure medicines, the ketogenic diet, and therapies for drug-resistant disease, including cannabidiol (CBD), felbamate, and sulthiame.
The authors report that approximately two-thirds of patients achieve seizure remission, while a substantial minority develop drug-resistant seizures, intellectual disability, and behavioral comorbidities. The review also discusses emerging treatments tailored to genetic causes such as SLC2A1, SLC6A1, SYNGAP1, CHD2, STXBP1, and SCN2A. Because this is a review, the abstract does not provide a separate estimate of CBD’s effectiveness or establish that it is superior to other treatments. This abstract-based summary cannot assess the full comparative evidence, safety details, or treatment effects for individual therapies.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.